109results about "Cyclic peptides" patented technology

The invention provides an anti-wrinkle combined cyclic peptide and application thereof in cosmetics, the anti-wrinkle combined cyclic peptide comprises cyclic pentapeptide-4, cyclic tripeptide-5 and cyclic hexapeptide-9, the combined cyclic peptide has a remarkable synergistic effect in the aspects of promoting expression of collagen genes Collagen I, Collagen III and Collagen IV and inhibiting acetylcholine secretion, the skin elasticity and glossiness are remarkably improved, and the anti-wrinkle combined cyclic peptide has a good anti-wrinkle effect. The generation of wrinkles is inhibited, and good anti-aging and wrinkle-removing effects are achieved.

The present disclosure relates to the technical field of polypeptides. Disclosed are a cyclic peptide, and a composition and the use thereof. The cyclic peptide of the present disclosure has a structure as shown in formula (I): Cyclo-[Gly-His-Lys-Lys] (I). The present disclosure specifically relates to the cyclic peptide or a salt thereof, or a composition thereof, and the use thereof in the preparation of a composition for caring or treating skin or mucosa.

The invention discloses a CAIX targeted degradation agent. The CAIX targeted degradation agent comprises a CAIX target protein ligand, an integrin ligand and a connector, the CAIX target protein ligand and the integrin ligand are connected through the connecting body. As the carbonic anhydrase IX is enriched in the tumor region, the CAIX targeted degradation agent can specifically target the tumor region; the compound can effectively induce degradation of CAIX and inhibit survival of tumor cells under the hypoxia condition, has the functions of targeting a tumor area and degrading carbonic anhydrase IX by utilizing integrin and lysosome, further changes hypoxia and subacid environments of the internal environment of a tumor patient, and plays a role in inhibiting survival of hypoxia tumor cells; the tumor targeting property is high, the toxic and side effects on normal cells are relatively small, and a relatively good effect can be obtained by using a relatively small dosage.

Compounds with the following structures and their analogs are provided. Compositions that include these structures can be used to inhibit glucose transporters and stop or decrease the proliferation of cancer, treat possible organ rejection and treat autoimmune disease.

To provide an amino acid capable of improving the membrane permeability of peptide compounds, as well as a peptide compound including the amino acid.SOLUTION: The present invention provides an amino acid having a side chain capable of forming at least one intramolecular hydrogen bond.SELECTED DRAWING: None

Disclosed is a peptide-immobilized bead library from which peptides are more likely to be obtained as candidates of useful substances such as pharmaceuticals, and with which the amino acid sequence bound to a target substance can be more easily analyzed, compared to known OPOB libraries. The peptide-immobilized bead library has a structure of General Formula [I]. In General Formula [I], X is an amino acid residue; n is an integer of 4 to 8; Y is a cyclization structure; A is a spacer structure; B is a specific cleavage site-containing structure; and the 4 to 8 amino acid residues of X are each independently randomly selected.

The present invention provides a flavor enhancing composition that can enhance a flavor of a food product when blended with the aforesaid food product, a method for producing the same, and a method for enhancing a flavor of a food product. A first embodiment of the present invention relates to a flavor enhancing composition containing one or more heat-treated spices selected from cumin, paprika, asafoetida and mustard seed. A second embodiment of the present invention relates to a method for producing the aforesaid flavor enhancing composition, comprising heating, under a specified condition, the one or more spices selected from cumin, paprika, asafoetida and mustard seed. A third embodiment of the present invention relates to a method for enhancing a flavor of a food product, comprising blending the aforesaid flavor enhancing composition with the food product.

The invention discloses a peptide with an anti-photoaging effect as well as a preparation method and application of the peptide. The cyclic dipeptide cyclo (LO) and the linear dipeptide LO disclosed by the invention can be used for remarkably inhibiting the activity of MMP-1 and efficiently blocking collagen degradation. In addition, the cyclic dipeptide and the linear dipeptide have no cytotoxic effect when being co-cultured with fibroblasts, so that the cyclic dipeptide and the linear dipeptide have no stimulation and side effects on cells, and are high in safety and good in stability. The cyclic dipeptide and the linear dipeptide disclosed by the invention can resist UVA (Ultraviolet A) damage, have a promoting effect on cell proliferation activity after UVA irradiation and have an anti-aging effect on cells after UVA irradiation. The two peptides disclosed by the invention can be used for preparing medicines or cosmetics for resisting light aging, resisting aging, beautifying and protecting skin. The peptide fragment disclosed by the invention has a good application prospect in the fields of medicines, cosmetics and the like.

The present invention provides therapeutic compounds, such as compounds of formula I, or pharma- ceutically acceptable salts, hydrates or solvates thereof, pharmaceutical compositions thereof, methods of use thereof, and methods for making these compounds, as therapeutic or anti-cancer agents.

The invention discloses a sulfur-containing gem-difluoroallyl compound as well as a preparation method and application thereof. The invention provides a preparation method of a compound as shown in a formula C. The preparation method comprises the following step: in a solvent, in the presence of alkali, carrying out gem-difluoroallylation reaction on a compound as shown in a formula A and a compound as shown in a formula B to obtain the compound as shown in the formula C. According to the method, the sulfydryl in the sulfydryl-containing compound can be mildly and efficiently gem-difluoroallylated, metal catalysis is not needed, the reaction can be performed in a water phase, the operation is simple, and the method is suitable for performing rapid fluoroalkylation modification and further functional modification on polypeptide, protein, complex bioactive molecules and the like; the method has very important application prospects in the fields of medicine, life science and the like.

Provided herein are methods for identifying a subject with cancer for treatment with a Psap peptides. The subject is identified based on a level of CD36. Also provided herein are compositions and methods for treatment of a subject with cancer based on a level of CD36.

To provide a new molecular modality capable of modulating the function of an undruggable target.SOLUTION: A compound (e.g., a macrocyclic compound comprising 14 to 40 ring atoms as shown below) capable of modulating a biological process by binding to presenter proteins (e.g., members of the FKBP family, members of the cyclophilin family, or PIN1) and target proteins (e.g., eukaryotic target proteins such as mammalian target proteins or fungal target proteins or prokaryotic target proteins such as bacterial target proteins).SELECTED DRAWING: None

The invention discloses a colla corii asini in-vivo bioactive component cyclic dipeptide and a discovery method thereof, and belongs to the technical field of bioactive component analysis and application. The method comprises the following steps: establishing a rat donkey-hide gelatin administration model and collecting a sample, performing solid-phase extraction on the sample, performing LC-MS / MS peptidomics analysis and PEAKS database search, screening exogenous oligopeptides based on a feature-based molecular network (FBMN), performing cyclic dipeptide targeted metabonomics identification, and verifying cell viability. According to the method, 29 cyclic dipeptides are produced by metabolism in donkey-hide gelatin, and the cyclic dipeptides containing hydroxyproline (Hyp) can significantly improve the survival rate of HT-22 cells damaged by glutamic acid or hydrogen peroxide induction and have neuroprotective activity.

The present disclosure provides a cyclic peptide derivative, a method for producing the same, and a composition. The present disclosure relates to a compound for modulating nervous system cell activity. More specifically, the compound of the present disclosure is capable of modulating the proliferation activity of astrocytes. The compound of the present disclosure has the effect of enhancing the proliferation activity of astrocytes. The features provided by the present disclosure can be used for a cyclic peptide derivative for modulating nervous system cell activity and a method for producing said cyclic peptide derivative.

Peptide compositions and methods for inhibiting angiogenesis, or pathological or abnormal blood vessel development, in a human or other animal subject are provided. The present invention provides a composition of matter comprising a peptide consisting of or including the amino acid sequence Arg-Ala-Glu.

The invention relates to a cyclic peptide for inhibiting a drug-resistant bacterium AcrB protein as well as a delivery vector and application of the cyclic peptide. The amino acid sequence of the cyclic peptide comprises any one of sequences as shown in SEQ ID No.1-SEQ ID No.15. The invention discloses a cyclic peptide inhibitor for reversing the drug resistance of antibiotics. The method comprises the following steps: firstly, designing and screening out cyclic peptide capable of forming high affinity with AcrB protein; secondly, the delivery carrier entraps the cyclopeptide to a bacterial membrane to cause membrane disturbance, the cyclopeptide enters the bacterial membrane to be combined with AcrB on an inner membrane to inhibit antibiotic excretion, the sensitivity of bacteria to the antibiotics is enhanced, and the MIC of the antibiotics is reduced.

Provided are a polypeptide-coupled drug and an anti-tumour use thereof. The polypeptide-coupled drug is a compound of formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), P is a cyclic peptide containing 4-9 amino acids, L is a linking group, and D is selected from topoisomerase I inhibitors; the polypeptide-coupled drug has better tumour growth inhibitory activity. P-L-D (I)

The present disclosure relates to cyclic oligopeptides that bind to interleukin-13 (IL-13), which are therapeutically useful in methods of treating or preventing IL-13-related skin disorders or conditions. The present disclosure also provides methods of treating or preventing an IL-13-related skin disorder or condition with an IL-13-binding cyclic oligopeptide. The present disclosure further provides methods of generating an IL-13-binding cyclic oligopeptide. The present disclosure provides cyclic oligopeptides that bind to IL-13, and methods of using such cyclic oligopeptides to treat IL-13-related skin disorders or conditions.

Cyclic peptides, their compositions and uses are disclosed, relating to the technical field of polypeptides. The cyclic peptides of the present disclosure have the structure shown in formula (I): Cyclo-[Gly-His-Lys-Lys] (I). Specifically, it relates to the use of the cyclic peptide or its salt, or their compositions, and their use in the preparation of compositions for caring for or treating the skin or mucous membranes.

The present invention relates to ligand-SIFA conjugates that contain two separate moieties within a single molecule: (a) one or more ligands capable of binding to a fibroblast activation protein (FAP), and (b) a silicon fluoride acceptor (SIFA) moiety that contains a covalent bond between a silicon atom and a fluorine atom.

The invention belongs to the technical field of gene engineering, and particularly relates to an NRPS gene, a vector and construction and preparation of a high-yield cyclic dipeptide compound recombinant strain of the NRPS gene. According to the invention, an NRPS core gene is excavated from a sea squirt-derived fungus Diapothesp.SYSU-MS4722, a recombinant strain is constructed by using the gene and using Aspergillus oryzae as a heterologous expression host, the cyclic dipeptide natural product cyclo (Phe-Ala) is successfully separated, and the yield can reach 110 mg / L, which is increased by 20 times compared with the yield of cyclo (Phe-Ala) in reported marine bacteria Pseudomonasputida. Therefore, the aspergillus oryzae recombinant strain disclosed by the invention can be used for efficiently preparing the cyclic dipeptide compound cyclo (Phe-Ala) and has an important application value.

The present disclosure relates to compositions and methods useful for the functionalization of surfaces in the absence of a metal catalyst. The compositions include compounds of formula (I), which react with strained alkene-containing compounds, before or after molecular assembly catalyzed by tyrosinase, to afford cycloadducts. The strained alkene-containing compound may further comprise any molecule of interest, including small molecules and macromolecules, thereby enabling surface functionalization. In certain embodiments, the strained alkene-containing molecule comprises a moiety selected from the group consisting of a trans-cyclooctene (TCO), cyclopropene, cyclobutene, and norbornene.

A bicyclic peptide composition and its application are disclosed, relating to the field of peptide technology. The cyclic peptide composition comprises component X and component Y, wherein component X is cyclic octapeptide-69, and component Y is selected from one or more of the following cyclic peptides: Cyclo-(Pro-Lys-Glu-Lys) and Cyclo-(Val-Leu-Gln-Trp-Val-Lys). Specifically, the cyclic peptide composition and its use in the preparation of cosmetics are disclosed.

Described herein is the monohydrochloride salt and the free zwitterion of the macrocyclic peptide antibiotic 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid. Also described are amorphous and crystalline forms of the hydrochloride salt and the free zwitterion, as well as methods of making them and using them in medical therapy.

Disclosed are methods of producing conditionally active proteins that target senescent cells and are conditionally active in the extracellular environment of senescent cells. The methods include methods of using an evolved protein library and testing using physiological concentrations of bodily fluid components. Also disclosed are conditionally active proteins, antibodies, and antibody fragments for killing or removing senescent cells, conjugates and pharmaceutical compositions using these conditionally active proteins, and methods of treating age-related diseases, conditions, or disorders using the pharmaceutical compositions. Conditionally active proteins can be further evolved, conjugated to other molecules, masked, and reduced in activity by linking cleavable moieties.

The invention discloses a novel PEG (Polyethylene Glycol) modified cyclic dipeptide compound. The modified cyclic dipeptide compound contains a cyclic dipeptide and a biocompatible polymer linked to the cyclic dipeptide. The cyclic dipeptide may be a cyclic dipeptide containing proline, a cyclic dipeptide containing hydroxyproline, or a cyclic dipeptide containing histidine. In one embodiment, the cyclic dipeptide is a ring (-his-pro). An exemplary modified cyclic dipeptide compound is represented by Formula A '. # imgabs0 #

Novel cyclic peptides, cyclic peptide conjugates and compositions containing them for treating neurological diseases in a subject include an Odorranalectin (OL) sequence or modified OL sequence as a scaffold and a biologically active peptide or protein and / or therapeutic agent conjugated thereto. Methods of treatment of neurological diseases are based on intranasal delivery of a cyclic peptide or cyclic peptide conjugate as described herein. Combinatorial libraries that include a plurality of cyclic peptides have also been developed and can be used to screen for a ligand(s) for a receptor of interest.

Disclosed are a bicyclic peptide composition and application thereof, and relate to the technical field of polypeptides, the ring peptide composition comprising component X and component Y, the component X being a ring hexapeptide-8, and the component Y being selected from one or more of the following ring peptides: a ring octapeptide-69, Cyclo-(Pro-Lys-Glu-Lys), Cyclo-(Val-Leu-Gln-Trp-Val-Lys). Specifically, the ring peptide composition and the use thereof in the preparation of cosmetics are disclosed.

Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural β-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.